Skip to content

DBV科技

US · DBVT #3611 按市值排名 上市于 2015
9.05 -0.06 -0.66%
实时 - 追踪5344个代码 - 心跳于305秒前 · 2026-10-16 16:04

估值 各估值倍数与自身5年区间的对比

市净率 3.83 高于历史水平 第70百分位
5年平均 7.79 · 在Biotechnology中排名第343/513
市盈率 -2.79 处于历史正常水平 第34百分位
5年平均 -2.33 · 前瞻 -3.66
市销率 --
5年平均 222.02 · 前瞻 16.90

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
DBV科技 (DBVT) 568.78M -2.59 3.54 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值10.79 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算19.3%。

合理价值

DBV Technologies SA receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $10.79 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 0.8 ranks in the bottom 20% compared with global peers. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be undervalued.

On a different note, the firm's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 16:04:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

DBV科技 讨论区 0 条评论

发表评论